Company intelligence / Profile preview
Nippon Zoki Pharmaceutical
Osaka, Osaka, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
Main marketed products for pain management, opioids (fentanyl, tramadol), and constipation; partnered with Surv Biopharma for Japan’s first full regulatory gene therapy approval for oncology (Surv.m-CRA-1), targeting rare bone cancer with planned approval by 2027.
- Therapeutic areas
- RheumatologyGastroenterologyDermatologyOncologyNeurology
- Modalities
- Small moleculeGene therapyOncolytic virus therapyProtein (Rabbit inflammatory skin extract)TF DecoyAllergen extract
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Surv Biopharma Inc. (gene therapy pipeline Surv.m-CRA-1)
Beyond the preview
Go deeper on Nippon Zoki Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nippon Zoki Pharmaceutical.